Table 2.
Univariate and multivariate analyses for overall survival of 149 HBsAg-positive cervical cancer patients.
| Variable | Univariate analysis for OS | Multivariate analysis for OS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| FIGO staging system | <0.001 | <0.001 | ||
| I | 1(Reference) | 1(Reference) | ||
| II | 3.697(1.521-8.986) | 3.623(1.426-9.201) | ||
| III | 8.834(3.496-22.325) | 10.362(3.590-29.908) | ||
| IV | 12.264(3.052-49.284) | 13.922(3.227-60.052) | ||
| Lymph nodes metastases | <0.001 | 0.001 | ||
| No | 1(Reference) | 1(Reference) | ||
| Yes | 3.208(1.855-5.548) | 2.754(1.550-4.894) | ||
| baseline serum AST levels (U/L) | 0.086 | 0.042 | ||
| ≤40 | 1(Reference) | 1(Reference) | ||
| >40 | 1.934(0.911-4.108) | 2.290(1.029-5.097) | ||
| Antiviral therapy | 0.039 | 0.017 | ||
| No | 1(Reference) | 1(Reference) | ||
| Yes | 0.342(0.123-0.948) | 0.280(0.098-0.799) | ||
| Treatment modality | <0.001 | <0.001 | ||
| RSA | 1(Reference) | 1(Reference) | ||
| DCRT/RRA | 5.131(1.209-21.769) | 1.129 (0.244-5.231) | ||
| RS-CRT/RS-R/C | 1.344(0.271-6.661) | 0.806(0.160-4.050) | ||
| other treatments | 13.038(3.055-55.652) | 4.911(1.100-21.922) | ||
HR, hazard ratio; 95% CI, 95% confidence interval; FIGO, International Federation of Gynecology and Obstetrics; AST, aspartate aminotransferase; RSA, radical surgery alone; DCRT/RRA, definitive chemoradiotherapy or radical radiotherapy alone; RS-CRT/RS-R/C, radical surgery combined with chemoradiotherapy or radical surgery combined with radiotherapy/chemotherapy; OS, overall survival.
P value was calculated using a Cox proportional hazards model.
Values in bold correspond to data showing significance.